Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001

A. Shaw(Massachusetts General Hospital), S.‐H.I. Ou(Chongqing University of Posts and Telecommunications), Stewart C. Wang(University of Michigan), Donghyeon Kim(Seoul National University), Geoffrey I. Shapiro(Brigham and Women's Hospital), Benjamin Solomon(Peter MacCallum Cancer Centre), Yung‐Jue Bang(Seoul National University), Tiziana Usari(Pfizer (Italy)), A. John Iafrate(Massachusetts General Hospital), Keith D. Wilner(Pfizer (United States)), Jeffrey W. Clark(Massachusetts General Hospital), D.R. Camidge(University of Colorado Cancer Center), G.J. Riely(Memorial Sloan Kettering Cancer Center), Marileila Varella‐Garcia(University of Colorado Anschutz Medical Campus)
Annals of Oncology
April 9, 2019
10.1093/annonc/mdz131
Cited by 587

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
|Nature Biotechnology|2014|2.3k